At 8:30 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading highe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37544 ARMATA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Washington 91-1549568 | ...

Exhibit 99.1 Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results LOS ANGELES, California, March 25, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen- specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its fourth quarter and full-year e ...

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results Accessibility StatementSkip Navigation LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult- to-treat bacterial infections, today announced financial results for its fo ...

Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update Accessibility StatementSkip NavigationLOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announc ...

Core Insights - Armata Pharmaceuticals, Inc. (ARMP) began trading on the New York Stock Exchange in May 2019 following a merger between C3J Therapeutics and AmpliPhi Biosciences Corporation [1] Group 1: Company Overview - Armata Pharmaceuticals focuses on the biotech sector, particularly in the development of innovative therapies [1] - The company is part of a broader trend in the biotech, pharma, and healthcare industries, which are experiencing significant movements and valuation changes [1] Group 2: Analyst Insights - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the investing group Haggerston BioHealth, which provides insights and analysis on over 1,000 companies in the biotech and healthcare sectors [1] - The investing group offers various resources, including catalysts for investment decisions, product sales forecasts, integrated financial statements, and market analyses [1]

Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts. H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the most promising stocks. On February 23, 2026, H.C. Wainwright increased the price target for ARMP from $9.00 to $15.00 and kept a Buy rating on the shares. The modification comes after the FDA designated AP-SA02 as a Qualified Infectious Diseas ...

FDA Approvals & Rejections - Armata Pharmaceuticals received FDA QIDP designation for AP-SA02, a bacteriophage-based candidate for complicated Staphylococcus aureus bacteremia, providing five years of market exclusivity and eligibility for Fast Track status [2][3] - Allurion Technologies gained FDA PMA approval for the Gastric Balloon System, a swallowable Smart Capsule that promotes fullness for about four months, targeting patients with a BMI of 30-40 [4][5] - Eton Pharmaceuticals' DESMODA oral solution was approved for managing central diabetes insipidus, with an expected peak annual sales of $30 million - $50 million [9][11] Deals - Gilead Sciences announced the acquisition of Arcellx for $115 per share, totaling an implied equity value of $7.8 billion, enhancing its position in cell therapy [12][13] - Vir Biotechnology entered a global collaboration with Astellas for VIR-5500, receiving $335 million in upfront payments and potential additional milestones of up to $1.37 billion [14][15][16] - Kairos Pharma signed a term sheet to acquire two oncology assets from Celyn Therapeutics, focusing on cancer therapeutics [17][18][20] Clinical Trials - Breakthroughs - MoonLake Immunotherapeutics reported positive Phase 2 trial results for Sonelokimab in axial spondyloarthritis, with 81% of patients achieving an ASAS40 response at Week 12 [21][22] - Novo Nordisk's CagriSema missed its primary endpoint in a Phase 3 trial against Zepbound, showing 23% weight loss compared to 25.5% with Tirzepatide [25][26][27] - Gossamer Bio's seralutinib missed the primary endpoint in the PROSERA Phase 3 study for pulmonary arterial hypertension, showing a placebo-adjusted improvement in Six-Minute Walk Distance [28][30][31] - Argenx's VYVGART met primary goals in the Phase 3 ADAPT OCULUS trial for ocular myasthenia gravis, demonstrating significant improvement in ocular scores [37][38][39]

its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC o ...

Core Viewpoint - Armata Pharmaceuticals has received FDA approval to advance its bacteriophage product candidate AP-SA02 to Phase 3 clinical trials for treating complicated Staphylococcus aureus bacteremia, marking a significant milestone in bacteriophage therapy development [1][2][3] Group 1: FDA Approval and Study Advancement - The FDA confirmed that data from the Phase 2a diSArm study supports the advancement of AP-SA02 to Phase 3, providing guidance on key study design elements [2] - The Phase 3 study is expected to begin in the second half of 2026, focusing on the superiority of AP-SA02 over current standard treatments [1][2] - Armata is addressing FDA comments related to Chemistry, Manufacturing, and Controls (CMC) and is preparing for a future Biologics License Application [2] Group 2: Study Details and Significance - The Phase 2a diSArm study was a randomized controlled trial that demonstrated the efficacy of phage therapy, representing a significant achievement for Armata [3][6] - The primary endpoint for the Phase 3 study will be clinical response at the end of best available antibiotic therapy and 28 days later [4] - The diSArm study was partially funded by a $26.2 million Department of Defense award, highlighting the support for innovative treatment options [7][8] Group 3: Company Overview and Commitment - Armata Pharmaceuticals focuses on developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant infections [9] - The company is advancing a pipeline of phage candidates targeting various pathogens, including Staphylococcus aureus [9] - Armata is committed to phage therapy development, utilizing in-house cGMP manufacturing to support commercialization efforts [9]